Codiak Biosciences

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Funding reportedLast round: Post ipo equity

BiotechnologySan Francisco, United States

What company datasets say Codiak Biosciences raised

Funding, as reported

Reported in all$257Min dollars

Rounds6

Last roundPost ipo equity

Last round dateSept 2022

Investors listed13

From the SEC filings it signed: 1 on the team.

On the board, as filediEric LanderNoubar AfeyanSteven Gillis

Investors who name them

Each firm lists Codiak Biosciences on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Codiak Biosciences in front of investors. Or tell us what we have wrong.